CME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CME Group Inc is not a strong buy for a beginner, long-term investor at this time. While the company has demonstrated strong financial performance and growth, the lack of clear positive trading signals, cautious congressional activity, and mixed analyst ratings suggest holding off on immediate investment. The stock's recent price increase and lack of significant positive catalysts make it less compelling for immediate entry.
The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone at 65.528, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level of 308.589, with resistance at 319.019 and support at 298.159. However, the RSI does not indicate an overbought or oversold condition, suggesting no immediate strong signal.
Strong financial performance in Q4 2025, with revenue up 39.14% YoY, net income up 35.23% YoY, and EPS up 35.00% YoY. Analysts highlight growth opportunities in prediction markets, tokenization, and crypto. Elevated trading volumes amid market volatility and new initiatives like the FanDuel partnership are also positive.
Congressional trading data shows 4 sale transactions with no purchases, indicating caution. Analysts are mixed, with some maintaining Underperform or Neutral ratings. The Chicago Fed President's comments on inflation suggest potential macroeconomic headwinds. Additionally, concerns raised by senators regarding prediction market contracts could impact CME's growth initiatives.
In Q4 2025, CME Group reported a 39.14% YoY increase in revenue to $3.425 billion, a 35.23% YoY increase in net income to $1.168 billion, and a 35.00% YoY increase in EPS to $3.24. These results indicate strong growth momentum.
Analyst ratings are mixed. Morgan Stanley and TD Cowen have raised price targets to $340 and $328, respectively, with Overweight and Buy ratings. However, BofA and JPMorgan maintain Underperform ratings with lower price targets of $232 and $266. UBS and Barclays remain Neutral or Equal Weight, reflecting cautious optimism. The average price target suggests limited upside from the current price.
